What question did this study set out to answer?

This study aimed to evaluate the safety and adverse events associated with upadacitinib in patients with inflammatory bowel disease in Greece.

P0800Real-world use of upadacitinib in Inflammatory Bowel Disease patients in Greece: Focus on adverse events

View Full Paper

Ask AI

Bookmark

This study aimed to evaluate the safety and adverse events associated with upadacitinib in patients with inflammatory bowel disease in Greece.
Retrospective review of medical records of IBD patients treated with upadacitinib.
Documented demographic and clinical characteristics, including adverse events during treatment.
Monitored severity and frequency of adverse events according to standard clinical practice.
Out of 77 patients, 23 (29.9%) experienced at least one adverse event during treatment.
Respiratory tract infections were the most common adverse event, occurring in 36.3% of cases.
40% of adverse events occurred during the induction phase of treatment; 20% led to permanent discontinuation of therapy.

No takes yet. Share an insight, caveat, or question.

In this retrospective review, upadacitinib treatment showed manageable adverse events in IBD patients, indicating its safety profile.

Neokleous et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark